Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hueber

Showing results (551-560 of 570) with videos related to

Pageof 57
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|December 24, 2021
Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated CohortDavid Simon, Koray Tascilar, Arnd Kleyer, et al.
Gut|October 14, 2022
Identification of bacterial lipopeptides as key players in IBSCamille Petitfils, Sarah Maurel, Gaelle Payros, et al.
Annals of the Rheumatic Diseases|June 22, 2016
Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugsCamille P Figueiredo, Holger Bang, Jayme Fogagnolo Cobra, et al.
Experimental Dermatology|April 2, 2015
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasisKristian Reich, Kim A Papp, Robert T Matheson, et al.
The Lancet. Rheumatology|February 1, 2024
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trialKoray Tascilar, Melanie Hagen, Arnd Kleyer, et al.
Nature Communications|July 26, 2020
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simon, Koray Tascilar, Gerhard Krönke, et al.
BMJ Open|January 8, 2025
Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseasesMelek Yalcin Mutlu, Arnd Kleyer, Gerhard Kroenke, et al.
Journal of Clinical Medicine|June 10, 2023
Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO TrialMarlene Stephan, Koray Tascilar, Melek Yalcin-Mutlu, et al.
Nature Cancer|June 17, 2024
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancersEmilie A Chapeau, Laurent Sansregret, Giorgio G Galli, et al.
Rheumatology (Oxford, England)|January 9, 2024
How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patientsConor Coyle, Lily Watson, Caroline Whately-Smith, et al.
Pageof 57

Showing results (551-560 of 570) with videos related to

Sort By:
Pageof 57
Arthritis & Rheumatology (Hoboken, N.J.)|December 24, 2021
Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated CohortDavid Simon, Koray Tascilar, Arnd Kleyer, et al.
Gut|October 14, 2022
Identification of bacterial lipopeptides as key players in IBSCamille Petitfils, Sarah Maurel, Gaelle Payros, et al.
Annals of the Rheumatic Diseases|June 22, 2016
Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugsCamille P Figueiredo, Holger Bang, Jayme Fogagnolo Cobra, et al.
Experimental Dermatology|April 2, 2015
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasisKristian Reich, Kim A Papp, Robert T Matheson, et al.
The Lancet. Rheumatology|February 1, 2024
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trialKoray Tascilar, Melanie Hagen, Arnd Kleyer, et al.
Nature Communications|July 26, 2020
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simon, Koray Tascilar, Gerhard Krönke, et al.
BMJ Open|January 8, 2025
Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseasesMelek Yalcin Mutlu, Arnd Kleyer, Gerhard Kroenke, et al.
Journal of Clinical Medicine|June 10, 2023
Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO TrialMarlene Stephan, Koray Tascilar, Melek Yalcin-Mutlu, et al.
Nature Cancer|June 17, 2024
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancersEmilie A Chapeau, Laurent Sansregret, Giorgio G Galli, et al.
Rheumatology (Oxford, England)|January 9, 2024
How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patientsConor Coyle, Lily Watson, Caroline Whately-Smith, et al.
Pageof 57